---
title: "eXoZymes Prices $18 Unit Equity Offering; MDB Capital Underwrites $5.33 Million Deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289090898.md"
description: "eXoZymes priced an $18 unit equity offering underwritten by MDB Capital, raising approximately $5.33 million gross. Each unit includes two shares and one warrant exercisable at $11.24 after one year. Net proceeds will fund NCT opportunities, next-in-line products, R&D, and general corporate purposes. VStock Transfer was appointed as the warrant agent to administer issuance and recordkeeping for the warrants."
datetime: "2026-06-08T18:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289090898.md)
  - [en](https://longbridge.com/en/news/289090898.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289090898.md)
generator: "portal-rs"
---

# eXoZymes Prices $18 Unit Equity Offering; MDB Capital Underwrites $5.33 Million Deal

eXoZymes entered two material agreements to execute a public units offering and administer its accompanying warrants. Under an Underwriting Agreement with MDB Capital, the company is selling units at $18.00, each comprising two shares and one warrant, for gross proceeds of about $5.33 million (with an over-allotment option that could lift proceeds to $6.13 million). Net proceeds will support NCT-related opportunities, next-in-line products, R&D, and general corporate purposes. A separate Warrant Agent Agreement with VStock Transfer will handle issuance and recordkeeping for warrants, which are exercisable after one year at $11.24 per share, expire five years from the offering date, and include redemption and reset provisions.

**Agreement 1: eXoZymes Prices $18 Unit Equity Offering; MDB Capital Underwrites $5.33 Million Deal**

-   **Agreement type**: Underwriting Agreement for firm commitment equity offering
-   **Counterparty**: MDB Capital
-   **Signed / Effective**: Jun 05 2026 / same
-   **Duration / Termination**: Through offering closing
-   **Reason**: Raise capital for development, R&D, and corporate purposes

**Agreement 2: eXoZymes Taps VStock Transfer as Warrant Agent for Units Offering**

-   **Agreement type**: Warrant Agent Agreement
-   **Counterparty**: VStock Transfer
-   **Signed / Effective**: Jun 05 2026 / same
-   **Duration / Termination**: Through five-year warrant term
-   **Reason**: Administer public warrants for offering

Original SEC Filing: EXOZYMES INC. \[ EXOZ \] - 8-K - Jun. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [EXOZ.US](https://longbridge.com/en/quote/EXOZ.US.md)
- [MDBH.US](https://longbridge.com/en/quote/MDBH.US.md)

## Related News & Research

- [Curia partners with eXoZymes to scale up NCT manufacturing process](https://longbridge.com/en/news/298343956.md)
- [Exozymes CEO Michael Heltzen reports $59,978 common share purchase](https://longbridge.com/en/news/297839167.md)
- [PMV Pharmaceuticals Enters Underwriting Agreement With TD Securities for ~$47 Million Offering](https://longbridge.com/en/news/297766378.md)
- [Lexaria Bioscience warrants exercised at reduced price of USD 12.92 per share](https://longbridge.com/en/news/298315424.md)
- [Tiger Gold issues 25,619,351 units after special warrants are deemed exercised](https://longbridge.com/en/news/298136109.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**